Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Alzheimer’s Disease: Behavioral Management

Alzheimer’s Disease: Behavioral Management CHAPTERS Alzheimer's Disease: Behavioral Management REBEKAH LoY, PI ERRE N. T AR JOT,* & K LARA ROSENQU IST D EPARTMENTS OF P SYCHIATRY AND NEUROLOGY UN IVERSITY OF R OCHfST£R M EDICAL CENTER, AND P ROCRAM IN NEUROBEHAVIORAL TH ERAPEUTICS M ONROE COMMUNITY H OSPITAL INTRODUCTION No med ica tion has been approved by th e U.S. Food and Drug Adminis­ tration for treatment of agitation or aggression associated with dementia, or any dia g nosis for that matter. Further, the Omnibus Budget Reconcili ­ a tion Act (OBRA ) g uidelines of 1987 restrict the use of psychotropics in patients with dementia who reside in nursing homes. However, absen t regulatory approval, clinicians a ttemp t to deal the best they ca n with agi­ tation on a case-by-case basis. They arc guided by consensus stateme nts regarding this issue, which support the use of psychotropics w hen ot her approaches fail, and by clinical tri als data, w hich ilre rapi dly emerging and can influence clinical decision making. In 1997, the American Psychi­ atric Associ ation issued practice guideli nes for the management of patients with dementia and behavior problems (A meri ca n PsychiatriC Association, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Gerontology & Geriatrics Springer Publishing

Alzheimer’s Disease: Behavioral Management

Loading next page...
 
/lp/springer-publishing/alzheimer-s-disease-behavioral-management-dLFvOU8OR3
Publisher
Springer Publishing
ISSN
0198-8794
eISSN
1944-4036
DOI
10.1891/0198-8794.19.1.136
Publisher site
See Article on Publisher Site

Abstract

CHAPTERS Alzheimer's Disease: Behavioral Management REBEKAH LoY, PI ERRE N. T AR JOT,* & K LARA ROSENQU IST D EPARTMENTS OF P SYCHIATRY AND NEUROLOGY UN IVERSITY OF R OCHfST£R M EDICAL CENTER, AND P ROCRAM IN NEUROBEHAVIORAL TH ERAPEUTICS M ONROE COMMUNITY H OSPITAL INTRODUCTION No med ica tion has been approved by th e U.S. Food and Drug Adminis­ tration for treatment of agitation or aggression associated with dementia, or any dia g nosis for that matter. Further, the Omnibus Budget Reconcili ­ a tion Act (OBRA ) g uidelines of 1987 restrict the use of psychotropics in patients with dementia who reside in nursing homes. However, absen t regulatory approval, clinicians a ttemp t to deal the best they ca n with agi­ tation on a case-by-case basis. They arc guided by consensus stateme nts regarding this issue, which support the use of psychotropics w hen ot her approaches fail, and by clinical tri als data, w hich ilre rapi dly emerging and can influence clinical decision making. In 1997, the American Psychi­ atric Associ ation issued practice guideli nes for the management of patients with dementia and behavior problems (A meri ca n PsychiatriC Association,

Journal

Annual Review of Gerontology & GeriatricsSpringer Publishing

Published: Jan 1, 1999

There are no references for this article.